Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Globe Newswire•11/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.